BioCardia Secures Japanese Patent for Imaging Software, Advances Japan Approval Bid
Event summary
- BioCardia has received allowance for a Japanese patent, ‘Target Site Selection, Entry, and Update with Automatic Remote Image Annotation,’ covering its Heart3D™ Fusion Imaging software.
- The patent protects the fusion of pre-operative CT/MRI scans with real-time X-ray imaging for procedure planning and navigation during CardiAMP cell therapy.
- BioCardia is targeting approval of CardiAMP and its Helix delivery system in Japan following a recent consultation with the Japanese PMDA.
- CardiAMP Cell Therapy has received FDA Breakthrough designation and utilizes a patient’s own bone marrow cells to treat ischemic heart failure.
- Upcoming events in May 2026 include meetings with the FDA CDRH and CBER regarding approval pathways.
The big picture
This patent allowance represents a significant step for BioCardia as it seeks to expand its commercial footprint beyond the US. The Japanese market presents a substantial opportunity for cell-based therapies, but regulatory hurdles and reimbursement challenges remain. Securing intellectual property rights is critical for protecting BioCardia’s competitive advantage in the increasingly crowded cardiac biotherapeutic landscape.
What we're watching
- Regulatory Risk
- The success of BioCardia’s Japan approval hinges on the PMDA’s assessment of CardiAMP’s safety and efficacy, and any unexpected requests for additional data could delay market entry.
- Partner Dynamics
- The ongoing collaboration with CART-Tech and the impact of their patents on BioCardia’s Heart3D offering warrants monitoring, as any disputes or shifts in the partnership could affect product development and intellectual property protection.
- Commercialization
- The ability of BioCardia to secure reimbursement for Heart3D as a cloud-based imaging software, similar to existing coronary artery disease diagnostic tools, will be crucial for its adoption and financial viability.
Related topics